Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00243

Submission Number:
00243
Commenter:
Kim Cadenhead
State:
Florida
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
I have been an independent pharmacist for over 20 years and have watched the demise of this significantly beneficial part of our communities. I implore the FTC to further investigate how the merger between Aetna and CVS will further devastate medication delivery to patients, certainly violating anti-trust laws that are meant to protect the public. This merger involves one of the nations largest PBMs (Pharmacy Benefit Managers), what I have begun to consider "legalized organized criminals," due to the wealth that they are acquiring while all patients continue to see the increase in the cost of medication. This process is so convoluted with PBMs almost being invisible to the public, that it is hard to explain but look at the million dollars in bonuses that these CEOs are receiving. Keep in mind that smaller retailers are fighting to survive as the PBMs pay almost nothing to the retailer. I have often wanted to request Dateline to do an investigative story on this incestuous relationship between the large retailers and the PBMs. Please do more investigation to understand the harm that this merger will perpetuate.